Critically ill patients increasingly can participate in life saving and life changing cell & gene therapy clinical trials without having to leave their homes with the Direct- to -Patient and Direct- from -Patient model. So how do you set up these supply chains? How do you mitigate risk? And how do you ensure they’re resilient? Mike Sweeney, QuickSTAT’s Global Head of Strategy for CGT and Direct to Patient products, explains.